Date Short Volume Total Volume Percent
2023-08-01 649,405 857,416 76%
is this correct ? 76 percent ?

Let MH do the confirming CVOT. Paid from his savings. I would ask a court to force him do so

Are these trials designed and approved by FDA as a confirmation of Reduce it trial (CVOT) ?

Kiwi and what comes after these two trials. What's next you will be talking about ? What other trials will be needed ?

We'll see if you're right

Are you AF or SN when you sold at 1,89 before another MO attack?

That is awesome ! Real world experience and results. But we should get such results from patients prescribed real Vascepa across US. That's not complicated I guess.

You and mostly Kiwi keep talking about trials... Why don't you ask real patients that are on real Vascepa for CVD indication. Prescription for this indication is here for about 2 years as I remember.Ask them whether Vascepa help them. This would be the best proof . Shouldn't be a problem to collect this data

https://worldtimetodays.com/amarin-has-a-big-decision-to-make-how-sarissa-capital-can-help-move-forward/

He had his questions, but those were clearly answered

For me it was such an unbelievable experience to listen to this Court hearing that I'm looking forward to hear Marjac at next hearing ! Clear and convincing at his best ! English is not my first language but I could understand everything !

Marjac please come to the stage among us so that we can give you a standing ovation !

Hoping for the best, prepared for the worst. Fingers crossed Marjac !

Good to see you back ! I hope you will stay, not just visiting. Your posts always inspired!

There was a nice volume in SP yesterday, SP went up by 9%, though short volume was up !
http://shortvolumes.com/?t=AMRN

It would be interesting to know whether Alex is on Vascepa himself ..and if yes, what are his experiences. that would be a PR !

Building IP: AMRN Patent Grant re "Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy"

United States Patent 11,229,618
Osterloh , et al. January 25, 2022
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Abstract
In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8846&pt=msg&mid=22866689

Conclusions For primary cardiovascular prevention, a combination therapy of icosapent ethyl plus statin is a cost-effective use of resources compared to statin monotherapy

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8843&pt=msg&mid=22829433

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8841&pt=msg&mid=22818724

https://www.shortablestocks.com/?amrn

have they increased cash position ?

Maybe because they waited for a patent ?

You're welcome !

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8834&pt=msg&mid=22798608

Nice. DDMMYYYY. 22022022

I hope they have a plan what to do next, that they stick to this plan and, unfortunately to us, they doesn't care about daily SP. I truly believe in this.

Another patent

Building IP: AMRN Patent Application re "METHODS OF TREATING MIXED DYSLIPIDEMIA"

United States Patent Application 20210379002
Kind Code A1
Osterloh; Ian ; et al. December 9, 2021
METHODS OF TREATING MIXED DYSLIPIDEMIA

Abstract
The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Inventors: Osterloh; Ian; (Kent, GB) ; Wicker; Pierre; (Mystic, CT) ; Braeckman; Rene; (Richboro, PA) ; Soni; Paresh; (Mystic, CT) ; Manku; Mehar; (Birmingham, GB)
Applicant:
Name City State Country Type

Amarin Pharmaceuticals Ireland Limited
Dublin
IE
Family ID: 1000005787114
Appl. No.: 17/393213
Filed: August 3, 2021

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8819&pt=msg&mid=22702171

Thank you for info

Sorry, they corrected it, it was 0,5g that they compared.

Can pls someone check Vascepa on Amazon pharmacy ? As I am not from States , I don't have access. I read something about it on other MB. Is it cheaper than GV or was it a spam ? ?

You're welcome

ICER analysis: Vascepa cost-effective at three times the cost




https://www.investorvillage.com/smbd.asp?mb=2294&mn=8812&pt=msg&mid=22676937




https://icer.org/wp-content/uploads/2021/05/Barriers-to-Fair-Access-Assessment-Final-Report-120121.pdf


/uploads/87669/files/Policy-Brief-Icosapent-Ethyl.pdf

I have the same problem, it takes almost a minute to open. filed feb and sept 2020


Building IP: AMRN Patent Grant re "Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy"

United States Patent 11,179,362
Osterloh , et al. November 23, 2021
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Abstract
In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Inventors: Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Manku; Mehar (Birmingham, GB)
Applicant:
Name City State Country Type

Amarin Pharmaceuticals Ireland Limited
Dublin
N/A
IE
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Family ID: 1000005950608
Appl. No.: 17/011,888
Filed: September 3, 2020


Buiding IP: AMRN Patent Grant re "Methods of reducing apolipoprotein C-III"

United States Patent 11,185,525
Manku , et al. November 30, 2021
Methods of reducing apolipoprotein C-III

Abstract
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Inventors: Manku; Mehar (Birmingham, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Zakrzewski; Joseph S. (Bedminster, NJ)
Applicant:
Name City State Country Type

Amarin Pharmaceuticals Ireland Limited
Dublin
N/A
IE
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Family ID: 1000005963339
Appl. No.: 16/786,788
Filed: February 10, 2020

I guess those two are different

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8808&pt=msg&mid=22668831

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8806&pt=msg&mid=22667898

28

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8685&pt=msg&mid=22348477

I really don't know. But the company may have a plan

https://uspto.report/patent/app/20210251941

https://www.investorvillage.com/smbd.asp?mb=2294&mn=8675&pt=msg&mid=22337384